Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
© 2023 The Korean Academy of Medical Sciences..
BACKGROUND: Before the omicron era, health care workers were usually vaccinated with either the primary 2-dose ChAdOx1 nCoV-19 (Oxford-AstraZeneca) series plus a booster dose of BNT162b2 (Pfizer-BioNTech) (CCB group) or the primary 2-dose BNT162b2 series plus a booster dose of BNT162b2 (BBB group) in Korea.
METHODS: The two groups were compared using quantification of the surrogate virus neutralization test for wild type severe acute respiratory syndrome coronavirus 2 (SVNT-WT), the omicron variant (SVNT-O), spike-specific IgG, and interferon-gamma (IFN-γ), as well as the omicron breakthrough infection cases.
RESULTS: There were 113 participants enrolled in the CCB group and 51 enrolled in the BBB group. Before and after booster vaccination, the median SVNT-WT and SVNT-O values were lower in the CCB (SVNT-WT [before-after]: 72.02-97.61%, SVNT-O: 15.18-42.29%) group than in the BBB group (SVNT-WT: 89.19-98.11%, SVNT-O: 23.58-68.56%; all P < 0.001). Although the median IgG concentrations were different between the CCB and BBB groups after the primary series (2.677 vs. 4.700 AU/mL, respectively, P < 0.001), they were not different between the two groups after the booster vaccination (7.246 vs. 7.979 AU/mL, respectively, P = 0.108). In addition, the median IFN-γ concentration was higher in the BBB group than in the CCB group (550.5 and 387.5 mIU/mL, respectively, P = 0.014). There was also a difference in the cumulative incidence curves over time (CCB group 50.0% vs. BBB group 41.8%; P = 0.045), indicating that breakthrough infection occurred faster in the CCB group.
CONCLUSION: The cellular and humoral immune responses were low in the CCB group so that the breakthrough infection occurred faster in the CCB group than in the BBB group.
| Errataetall: |
CommentIn: J Korean Med Sci. 2023 May 22;38(20):e185. - PMID 37218356 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Journal of Korean medical science - 38(2023), 20 vom: 22. Mai, Seite e155 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Choi, Seong-Ho [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
82115-62-6 |
|---|
| Anmerkungen: |
Date Completed 24.05.2023 Date Revised 25.05.2023 published: Electronic CommentIn: J Korean Med Sci. 2023 May 22;38(20):e185. - PMID 37218356 Citation Status MEDLINE |
|---|
| doi: |
10.3346/jkms.2023.38.e155 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35720803X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35720803X | ||
| 003 | DE-627 | ||
| 005 | 20231226072106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3346/jkms.2023.38.e155 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM35720803X | ||
| 035 | |a (NLM)37218354 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Choi, Seong-Ho |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.05.2023 | ||
| 500 | |a Date Revised 25.05.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a CommentIn: J Korean Med Sci. 2023 May 22;38(20):e185. - PMID 37218356 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Korean Academy of Medical Sciences. | ||
| 520 | |a BACKGROUND: Before the omicron era, health care workers were usually vaccinated with either the primary 2-dose ChAdOx1 nCoV-19 (Oxford-AstraZeneca) series plus a booster dose of BNT162b2 (Pfizer-BioNTech) (CCB group) or the primary 2-dose BNT162b2 series plus a booster dose of BNT162b2 (BBB group) in Korea | ||
| 520 | |a METHODS: The two groups were compared using quantification of the surrogate virus neutralization test for wild type severe acute respiratory syndrome coronavirus 2 (SVNT-WT), the omicron variant (SVNT-O), spike-specific IgG, and interferon-gamma (IFN-γ), as well as the omicron breakthrough infection cases | ||
| 520 | |a RESULTS: There were 113 participants enrolled in the CCB group and 51 enrolled in the BBB group. Before and after booster vaccination, the median SVNT-WT and SVNT-O values were lower in the CCB (SVNT-WT [before-after]: 72.02-97.61%, SVNT-O: 15.18-42.29%) group than in the BBB group (SVNT-WT: 89.19-98.11%, SVNT-O: 23.58-68.56%; all P < 0.001). Although the median IgG concentrations were different between the CCB and BBB groups after the primary series (2.677 vs. 4.700 AU/mL, respectively, P < 0.001), they were not different between the two groups after the booster vaccination (7.246 vs. 7.979 AU/mL, respectively, P = 0.108). In addition, the median IFN-γ concentration was higher in the BBB group than in the CCB group (550.5 and 387.5 mIU/mL, respectively, P = 0.014). There was also a difference in the cumulative incidence curves over time (CCB group 50.0% vs. BBB group 41.8%; P = 0.045), indicating that breakthrough infection occurred faster in the CCB group | ||
| 520 | |a CONCLUSION: The cellular and humoral immune responses were low in the CCB group so that the breakthrough infection occurred faster in the CCB group than in the BBB group | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antibodies | |
| 650 | 4 | |a Health Personnel | |
| 650 | 4 | |a Interferons | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Vaccination | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a ChAdOx1 nCoV-19 |2 NLM | |
| 650 | 7 | |a B5S3K2V0G8 |2 NLM | |
| 650 | 7 | |a Interferon-gamma |2 NLM | |
| 650 | 7 | |a 82115-62-6 |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Park, Ji Young |e verfasserin |4 aut | |
| 700 | 1 | |a Kweon, Oh Joo |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Joung Ha |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Min-Chul |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Yaeji |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Jin-Won |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Korean medical science |d 1995 |g 38(2023), 20 vom: 22. Mai, Seite e155 |w (DE-627)NLM012649317 |x 1598-6357 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:20 |g day:22 |g month:05 |g pages:e155 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3346/jkms.2023.38.e155 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 20 |b 22 |c 05 |h e155 | ||